Cargando…

Uniform multidrug therapy for leprosy – time for a rethink?

Detalles Bibliográficos
Autor principal:	Saunderson, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345294/ https://www.ncbi.nlm.nih.gov/pubmed/28256456 http://dx.doi.org/10.4103/0971-5916.200884

Ejemplares similares

International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes
por: Manickam, Ponnaiah, et al.
Publicado: (2016)

The end of leprosy is not imminent, but it is on the horizon
por: Saunderson, Paul, et al.
Publicado: (2022)

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
por: Cruz, Rossilene Conceição da Silva, et al.
Publicado: (2017)

It is time to rethink tactics in the fight against malaria
por: Slutsker, Laurence, et al.
Publicado: (2013)

Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach
por: Cruz, Rossilene Conceição da Silva, et al.
Publicado: (2018)

Health Policy Education for Medical Students: Time to Rethink?
por: Crosson, Francis J, et al.
Publicado: (2023)

Staff well‐being: Is it time to rethink implications for work schedules?
por: Nisbet, Gillian
Publicado: (2022)

Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil
por: Hungria, Emerith Mayra, et al.
Publicado: (2016)

Regional citrate anticoagulation in patients with liver failure - time for a rethink?
por: Patel, Sameer, et al.
Publicado: (2012)

Rethinking the Initial Board Certification Exam
por: Greenky, David, et al.
Publicado: (2021)

Rethinking the use of ‘vulnerable’
por: Munari, Stephanie C., et al.
Publicado: (2021)

Registered Reports: Time to Radically Rethink Peer Review in Health Economics
por: Clarke, Philip, et al.
Publicado: (2020)

Emergence and Transmission of Drug-/Multidrug-resistant Mycobacterium leprae in a Former Leprosy Colony in the Brazilian Amazon
por: Rosa, Patrícia S, et al.
Publicado: (2020)

Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles
por: Daldrup-Link, Heike E.
Publicado: (2017)

Rethinking COVID-19 vaccine allocation: it is time to care about our neighbours
por: Contreras, Sebastian, et al.
Publicado: (2021)

The curious case of an internal pilot in a multicentre randomised trial—time for a rethink?
por: Cook, Jonathan Alistair, et al.
Publicado: (2016)

Rethinking the Antibiotic Discovery Paradigm
por: Hancock, Robert E.W.
Publicado: (2015)

Rethinking marketing: back to purpose
por: Fehrer, Julia A.
Publicado: (2020)

Rethinking external assistance for health
por: Shroff, Zubin Cyrus, et al.
Publicado: (2022)

Rethinking Patient Engagement in Cancer Research
por: Schuster, Anne L. R., et al.
Publicado: (2022)

Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs: An Opportunity for Change in the Time of COVID-19
por: Jawa, Raagini, et al.
Publicado: (2022)

Time to rethink the systematic review catechism? Moving from ‘what works’ to ‘what happens’
por: Petticrew, Mark
Publicado: (2015)

Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
por: Ambruso, Sophia L.
Publicado: (2021)

Rethinking Biosafety in Research on Potential Pandemic Pathogens
por: Lipsitch, Marc, et al.
Publicado: (2012)

Global leprosy program: Does it need uniform-multi-drug therapy now?
por: Rao, P. Narasimha, et al.
Publicado: (2015)

Rethinking T cell immunity in oropharyngeal candidiasis
por: Pirofski, Liise-anne, et al.
Publicado: (2009)

Rethinking the Goals of Diabetes Prevention Programs
por: Mezuk, Briana, et al.
Publicado: (2021)

A Call to Rethink Nursing Education in Zimbabwe
por: Chigangaidze, Kudzanayi A. N.
Publicado: (2022)

The Missing Millions: A Threat to the Elimination of Leprosy
por: Smith, William Cairns, et al.
Publicado: (2015)

Learning from Sisyphus: time to rethink our current, ineffective strategy on neurodevelopmental environmental toxicants
por: Takser, Larissa, et al.
Publicado: (2020)

Surgical removal of superficial peritoneal endometriosis for managing women with chronic pelvic pain: time for a rethink?
por: Horne, AW, et al.
Publicado: (2019)

The need for uniform and coordinated practices involving centrally manufactured cell therapies
por: Stroncek, David, et al.
Publicado: (2022)

Single‐cell isogrowth profiling: Uniform inhibition uncovers non‐uniform drug responses
por: Lukačišin, Martin, et al.
Publicado: (2022)

Rethinking the politics and implementation of health in all policies
por: Wismar, Matthias, et al.
Publicado: (2013)

Rethink Respiratory Rate for Diagnosing Childhood Pneumonia
por: Amirav, Israel, et al.
Publicado: (2019)

Global practices in regard to implementation of preventive measures for leprosy
por: Gillini, Laura, et al.
Publicado: (2017)

Pharmacist Rethink through a Planetary Health Lens
por: Maharaj, Sandeep, et al.
Publicado: (2021)

Progression of leprosy disability after discharge: is multidrug therapy enough?
por: Sales, Anna Maria, et al.
Publicado: (2013)

Gene expression patterns associated with multidrug therapy in multibacillary leprosy
por: Ferreira, Helen, et al.
Publicado: (2022)

Progressive neuropathy in patients with lepromatous leprosy after multidrug therapy
por: Penna, Patricia Sola, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3erabdvcbrd19roomucbp38s36